Affiliated Managers Group Inc
Financial Services
Affiliated Managers Group Inc (AMG) Stock News
The latest AMG headlines and market coverage — 7 recent stories, updated throughout the day.
- Zacks Investment Research·
Will Affiliated Managers (AMG) Beat Estimates Again in Its Next Earnings Report?
Affiliated Managers Group (AMG) has demonstrated a strong streak of beating earnings estimates in recent quarters, with an average beat of 3.61% over the last two reports. The company currently has a positive Earnings ESP of +1.62% combined with a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in the upcoming report. Stocks with this combination historically beat consensus estimates nearly 70% of the time.
- Zacks Investment Research·Neutral
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
Amgen stock gained 2.6% to close at $413.08, outperforming the broader market decline. The biotech giant is projected to report EPS of $5.69 (up 0.89% YoY) and revenue of $9.91 billion (up 3.68% YoY). For the full year, consensus estimates project earnings of $22.94 per share and revenue of $38.81 billion. Amgen holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 17.55, trading at a discount to its industry average.
- Zacks Investment Research·Neutral
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen has recently been a trending stock, with shares down 7.8% over the past month compared to the S&P 500's +0.8% gain. The biotech company shows solid fundamentals with consistent earnings and revenue beat history, but the Zacks Rank #3 (Hold) rating suggests it may perform in line with the broader market in the near term. Current year earnings are expected to grow 5% with revenue growth of 5.6%, while the stock trades at par with peers based on valuation metrics.
- Zacks Investment Research·
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide is entering a competitive obesity market dominated by Novo Nordisk and Eli Lilly. The drug showed up to 20% average weight loss in phase II trials and offers a key advantage with once-monthly or less-frequent dosing compared to weekly injections from competitors. While MariTide trails competitors' efficacy and market presence, the massive obesity market projected to reach $114 billion by 2030 could support multiple players, allowing MariTide to carve out a meaningful position based on convenience and adherence.
- Zacks Investment Research·
AMG vs. BLK: Which Stock Is the Better Value Option?
Affiliated Managers Group (AMG) and BlackRock (BLK) are compared as potential value investments in the Financial - Investment Management sector. AMG holds a stronger Zacks Rank #2 (Buy) versus BLK's #3 (Hold), with superior valuation metrics including a lower forward P/E ratio of 9.83 compared to BLK's 20.19, and a better Value grade of B versus D. AMG is identified as the more attractive value opportunity based on improving earnings outlook and fundamental metrics.
- GlobeNewswire Inc.·
AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class Action Investigation into Exposure of Patient Health Information
Amgen Inc. disclosed a material data breach in July 2026 involving unauthorized access to cloud environments hosted by third-party providers, resulting in the exfiltration of patient protected health information and proprietary company data. The national class action law firm Edelson Lechtzin LLP is investigating potential legal claims on behalf of affected individuals and offering free case evaluations.
- Yahoo Finance·Bullish
Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings